[1]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-US2008/194529,2008,A1Locationinpatent:Page/Pagecolumn59
[2]CurrentPatentAssignee:DONG-ASOCIOHOLDINGSCO.,LTD.-WO2010/13925,2010,A2Locationinpatent:Page/Pagecolumn6
[3]CurrentPatentAssignee:MEZZIONPHARMACO.,LTD.-WO2006/132460,2006,A1Locationinpatent:Page/Pagecolumn7
[1]CurrentPatentAssignee:DONG-ASOCIOHOLDINGSCO.,LTD.-WO2010/95849,2010,A2Locationinpatent:Page/Pagecolumn10-11
[1]CurrentPatentAssignee:DONG-ASOCIOHOLDINGSCO.,LTD.-WO2010/95849,2010,A2Locationinpatent:Page/Pagecolumn12-13
[1]CurrentPatentAssignee:DONG-ASOCIOHOLDINGSCO.,LTD.-WO2010/95849,2010,A2Locationinpatent:Page/Pagecolumn13
[1]CurrentPatentAssignee:DONG-ASOCIOHOLDINGSCO.,LTD.-WO2010/95849,2010,A2Locationinpatent:Page/Pagecolumn12
Title: Chronic administration of udenafil, a selective phosphodiesterase type 5 inhibitor, promotes erectile function recovery in an animal model of bilateral cavernous nerve crush injury.
Journal: The journal of sexual medicine 20110501
Title: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20080601
Title: Transport of a new erectogenic udenafil in Caco-2 cells.
Journal: Archives of pharmacal research 20070901
Title: DA-8159 reverses selective serotonin reuptake inhibitor-induced erectile dysfunction in rats.
Journal: Urology 20050101
Title: Paick, J.S., et al., The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5(4): p. 946-53.
Title: Zhao, C., et al., Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int, 2011. 107(12): p. 1943-7.